Molecular basis of partial lipodystrophy and prospects for therapy
- 1 March 2001
- journal article
- review article
- Published by Elsevier in Trends in Molecular Medicine
- Vol. 7 (3), 121-126
- https://doi.org/10.1016/s1471-4914(01)01930-x
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Identification of a Novel Retinoic Acid-Responsive Element within the Lamin A/C PromoterBiochemical and Biophysical Research Communications, 2000
- LMNA, encoding lamin A/C, is mutated in partial lipodystrophyNature Genetics, 2000
- Pushing the envelope on lipodystrophyNature Genetics, 2000
- Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System DiseaseNew England Journal of Medicine, 1999
- Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophyThe Lancet, 1999
- Adipose Tissue Distribution Pattern in Patients with Familial Partial Lipodystrophy (Dunnigan Variety)Journal of Clinical Endocrinology & Metabolism, 1999
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γCurrent Opinion in Genetics & Development, 1995
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994
- LIPODYSTROPHY AND HEPATOMEGALY WITH DIABETES, LIPÆMIA, AND OTHER METABOLIC DISTURBANCES: A CASE THROWING NEW LIGHT ON THE ACTION OF INSULINThe Lancet, 1946